Cullen Frost Bankers Inc. Buys 5,926 Shares of Abbott Laboratories $ABT

Cullen Frost Bankers Inc. increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.5% during the 3rd quarter, Holdings Channel reports. The fund owned 177,191 shares of the healthcare product maker’s stock after acquiring an additional 5,926 shares during the period. Cullen Frost Bankers Inc.’s holdings in Abbott Laboratories were worth $23,733,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Commerzbank Aktiengesellschaft FI raised its stake in Abbott Laboratories by 9.3% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 245,168 shares of the healthcare product maker’s stock worth $32,838,000 after buying an additional 20,825 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Abbott Laboratories by 0.6% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 191,900 shares of the healthcare product maker’s stock worth $25,828,000 after purchasing an additional 1,111 shares in the last quarter. Whittier Trust Co. grew its position in Abbott Laboratories by 0.4% in the 3rd quarter. Whittier Trust Co. now owns 402,386 shares of the healthcare product maker’s stock valued at $54,157,000 after purchasing an additional 1,570 shares during the period. CIBC Asset Management Inc increased its stake in Abbott Laboratories by 0.8% during the 3rd quarter. CIBC Asset Management Inc now owns 579,308 shares of the healthcare product maker’s stock valued at $77,501,000 after purchasing an additional 4,476 shares in the last quarter. Finally, Sagespring Wealth Partners LLC raised its holdings in Abbott Laboratories by 14.6% during the third quarter. Sagespring Wealth Partners LLC now owns 33,760 shares of the healthcare product maker’s stock worth $4,522,000 after buying an additional 4,313 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Down 1.1%

NYSE ABT opened at $107.46 on Friday. The business’s fifty day moving average is $124.77 and its 200-day moving average is $128.33. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The stock has a market capitalization of $186.86 billion, a price-to-earnings ratio of 28.89, a PEG ratio of 1.78 and a beta of 0.72. Abbott Laboratories has a one year low of $105.78 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be paid a $0.63 dividend. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: MedTech and pharma strength, and EPS resilience — Abbott reported adjusted Q4 EPS growth (company highlighted margin improvements) and strong MedTech (+~12%) and Established Pharma (+~9%) performance that partly offset Nutrition weakness; management still projects FY‑2026 adjusted EPS growth. Press Release
• Positive Sentiment: Analysts keep buy/outperform stance despite cuts — several major firms trimmed price targets after the print but largely maintained buy/overweight ratings, signaling conviction in the longer‑term story even as near‑term expectations were tempered. Analyst Reaction
• Positive Sentiment: Some commentators view the pullback as a buying opportunity — market commentators highlight ABT’s dividend history, cash flow and buyback capacity, suggesting the drop may create an attractive entry for long‑term investors. MarketBeat: Pullback Analysis
• Neutral Sentiment: Full earnings call and transcripts available — investors can review management commentary and segment detail in the Q4 earnings call transcript for color on nutrition, diagnostics and Exact/other strategic items. Earnings Transcript
• Neutral Sentiment: Dividend/valuation commentary circulates — value and dividend‑focused outlets are flagging ABT as attractively valued after the pullback; this is background context rather than a near‑term catalyst. Zacks: Value Take
• Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics — Q4 revenue (~$11.5B) fell short of consensus, with Nutrition down sharply (~8–9%) and Diagnostics weak, sparking the initial selloff. Reuters: Revenue Miss
• Negative Sentiment: Guidance slightly below Street — Abbott set Q1 EPS and FY‑2026 EPS ranges that sit near or a touch below consensus, increasing near‑term revenue/growth concerns. Guidance Details
• Negative Sentiment: Multiple price‑target cuts — a raft of firms (Citigroup, Goldman, Raymond James, Sanford Bernstein, Oppenheimer, RBC, etc.) trimmed targets, which can amplify selling pressure even if ratings remain constructive. Benzinga: PT Cuts
• Negative Sentiment: Options and hedging activity spiked — an unusual surge in put buying suggests traders are positioning for further near‑term downside (heightened bearish sentiment).
• Negative Sentiment: Regulatory scrutiny in India — reports of an investigation into alleged misuse of a codeine‑based cough syrup (Abbott Healthcare) add an extra headline risk in emerging markets. Reuters: India Scrutiny

Wall Street Analyst Weigh In

Several research firms have recently commented on ABT. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. Sanford C. Bernstein decreased their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday. Barclays raised their target price on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Abbott Laboratories in a report on Monday, December 29th. Finally, The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $140.79.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.